CorMedix (CRMD) Stock: Buy, Sell, or Hold?
CRMD - CorMedix Inc.
$7.83
-0.13 (-1.70%)
âŧ
5d:
-7.62%
30d:
+10.21%
90d:
-12.67%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When CRMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CRMD is fairly priced but lacks strong directional signals. At 49.9% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CRMD is fairly priced but lacks strong directional signals. At 49.9% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CRMD is currently trading at $7.83, which is considered fair relative to its 30-day fair value range of $7.57 to $8.43. From a valuation perspective, the stock is trading at a premium (Forward PE: 130.4) compared to its historical average (38.7). At these levels, the market is pricing in 49.9% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, CRMD is showing sideways momentum. The price is currently testing key support at $7.82. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CRMD scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $15.40 (+96.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRMD is showing sideways momentum. The price is currently testing key support at $7.82. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CRMD scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $15.40 (+96.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$7.57 -
$8.43
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
45.2%
Protect Your Profits
Holding CRMD? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 96.8% below Wall St target ($15.40)
- BEARISH: Market expects 49.9% growth - appears too optimistic based on history
- WARNING: Composite score 41/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.57 -
$8.43
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$7.82
Resistance Level
$8.75
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
130.42
Wall Street Target
$15.40
(+96.8%)
Revenue Growth (YoY)
156.5%
Earnings Growth (YoY)
6.7%
Profit Margin
40.5%
Valuation Premium vs History
+49.9% premium
PE vs Historical
130.4 vs 38.7
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+49.9%
(market-implied from PE analysis)
1-Year Target
$11.73
(+50%)
2-Year Target
$17.58
(+125%)
3-Year Target
$26.36
(+237%)
3-Yr Target (if PE normalizes)
(PE: 130â39)
PE COMPRESSION
$7.82
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 130.4, Growth: -87.7%)
$5.70
(+-27%)
Base:
(SPY PE: 20.2, Growth: -87.7%)
$0.88
(-89%)
Bear:
(PE: 17.1, Growth: -87.7%)
$0.75
(-90%)
đ
Valuation based on Current Earnings
Trailing PE: 3.72 | Current EPS (TTM): $2.14
Bull Case
$4.38
(-44%)
Analyst growth -50.0%, PE expands to 4.1
Base Case
$3.98
(-49%)
Market implied -50.0%, PE stable at 3.7
Bear Case
$5.41
(-31%)
Severe decline -20.0%, PE contracts to 3.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 13, 2026 9:46 PM ET
Data refreshes hourly during market hours. Next update: 10:46 PM
Data refreshes hourly during market hours. Next update: 10:46 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$849 | 50 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$48 | 44 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$290 | 59 HOLD |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 41 HOLD |
Advanced CRMD Option Strategies
Professional options setups generated by AI based on today's CRMD price and gamma walls.
